Magnolia Medical Technologies

Magnolia Medical Technologies develops diagnostic solutions focused on reducing blood culture contamination and improving sepsis diagnostic accuracy. The company's flagship product is the Steripath® Micro Initial Specimen Diversion Device®, an FDA 510(k)-cleared device designed to reduce false-positive blood culture results in sepsis testing. The Steripath Platform is offered in two configurations: Steripath Micro for Direct to Media and Steripath Micro for Syringe Draws, supporting both peripheral venipuncture and peripheral IV start collection methods. Clinical studies demonstrate 83–88% contamination rate reduction depending on collection method. The device addresses a critical clinical challenge: blood culture contamination and misdiagnosis lead to unnecessary broad-spectrum antibiotic use, driving antibiotic resistance, Clostridioides difficile infections, and an estimated $6 billion in annual U.S. healthcare waste. Magnolia's platform is trusted by major hospital systems and health networks including Ascension, Premier, Cardinal Health, VA, Vizient, and HealthTrust, with clinical validation published in peer-reviewed journals including Clinical Infectious Diseases, Journal of Hospital Infection, and American Journal of Medical Quality. The company emphasizes diagnostic stewardship and quality outcomes improvement, with recognition from Newsweek for infection prevention innovation.